Zylox-Tonbridge Medical Technology Co (FRA:818) ROCE % : -2.76% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Zylox-Tonbridge Medical Technology Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zylox-Tonbridge Medical Technology Co's annualized ROCE % for the quarter that ended in Dec. 2023 was -2.76%.

Zylox-Tonbridge Medical Technology Co ROCE % Historical Data

The historical data trend for Zylox-Tonbridge Medical Technology Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zylox-Tonbridge Medical Technology Co ROCE % Chart

Zylox-Tonbridge Medical Technology Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-37.78

-31.70

-11.20

-3.56

-2.45

Zylox-Tonbridge Medical Technology Co Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial				-13.04	-1.61	-5.51	-2.19	-2.76

Zylox-Tonbridge Medical Technology Co ROCE % Calculation

Zylox-Tonbridge Medical Technology Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-9.951	/	( ( (440.565 - 20.593)	+	(433.534 - 40.812) )	/ 2 )
	=	-9.951	/	( (419.972	+	392.722)	/ 2 )
	=	-9.951	/	406.347
	=	-2.45 %

Zylox-Tonbridge Medical Technology Co's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-10.944	/	( ( (424.948 - 25.218)	+	(433.534 - 40.812) )	/ 2 )
	=	-10.944	/	( ( 399.73	+	392.722 )	/ 2 )
	=	-10.944	/	396.226
	=	-2.76 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

Zylox-Tonbridge Medical Technology Co (FRA:818) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zylox-Tonbridge Medical Technology Co ROCE % Related Terms

Thank you for viewing the detailed overview of Zylox-Tonbridge Medical Technology Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zylox-Tonbridge Medical Technology Co (FRA:818) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zylox-Tonbridge Medical Technology Co Ltd (FRA:818) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

02190:Hong Kong

Address

No. 18 Keji Avenue, Yuhang Street, 1st & 2nd Floors, Building 1, Yuhang District, Zhejiang Province, Hangzhou, CHN

Website

https://www.zyloxtb.com

Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries.

Zylox-Tonbridge Medical Technology Co (FRA:818) Headlines

No Headlines